Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2018 / N 3

Безопасность иммуносупрессорных препаратов, изменяющих течение рассеянного склероза
И.Д. Столяров, А.М. Петров, М.В. Вотинцева, Е.В. Ивашкова

References

1. Gusev EI, Boyko AN, Stolyarov ID. A multiple sclerosis glossary of terms. 2nd ed., revised. Moscow: Zdorovye cheloveka; 2015. 436 p. (In Russian).
2. Nikiforova IG, Ilves AG, Votintseva MV, Ivaskova EV, Petrov AM, Ogurtsov RP, Pozdnyakov AV, Stolyarov ID. Immunological studies in the diagnosis of multiple sclerosis. Neurological Journal 2003;8(5):9-13 (In Russian).
3. Stolyarov ID, Petrov AM, Votintseva MV, Ivashkov EV. Neuroimmunology: theoretical and clinical aspects. Human Physiology 2013;39(1):51-9 (In Russian).
4. Multiple sclerosis: diagnosis, treatment, specialists. Stolyarov ID, Boyko AN. Saint Petersburg: Elbi-SPb; 2008. 320 p. (In Russian).
5. Shkilnyuk GG, Ilves AG, Petrov AM, Prakhova LN, Kataeva GV, Reznikova TN, Stolyarov ID. Cognitive disturbances and brain glucose metabolic changes correlation in multiple sclerosis patients. Vestnik Rossiyskoy Voenno-Meditsinskoy Academii 2012;1(37):121-5 (In Russian).
6. Votintseva MV, Mineev KK, Petrov AM, Ilves AG, Reznikova TN, Stolyarov ID. The relationship between cognitive impairment and localization of white matter lesions in patients with multiple sclerosis. SS Korsakov Journal of Neurology and Psychiatry 2014;114(10-2):57-60 (In Russian).
7. Stolyarov ID, Petrov AM, Shkilnyuk GG, Kataeva GV, Prakhova LN. Positron emission tomography possibilities for studying the mechanisms of multiple sclerosis development: literature and own data. SS Korsakov Journal of Neurology and Psychiatry 2016;116(2-2):27-31 (In Rusian).
8. Stolyarov ID, Petrov MA, Votintseva MV. Cortical atrophy in multiple sclerosis and efficacy of disease modifying therapy. Nervous diseases 2017;4:10-7 (In Russian).
9. Kudryavtsev IV, Crobinets II, Mineev KK, Serebryakova MK, Petrov AM, Stolyarov ID. Peripheral blood T helper lymphocytes subsets in multiple sclerosis. Cytokines and Inflammation 2016;15(1):91-9 (In Russian).
10. Kudryavtsev IV, Ilves AG, Crobinets II, Mineev KK, Serebryakova MK, Petrov AM, Stolyarov ID. Peripheral blood B cell subsets in multiple sclerosis. Russian Journal of Immunology 2017;2:150-4 (In Russian).
11. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. The efficiency of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology 2009 Mar;256(3):405-15.
12. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology 2008 Jul;71(5):357-64.
13. Schmidt TE. Natalizumab treatment in relapsing-remitting multiple sclerosis. The Neurological Journal 2014:3:57-61 (In Russian).
14. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Archives of Neurology 2011 Feb;68(2):186-91.
15. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X. Significant clinical worsening after natalizumab withdrawal: predictive factors. Multiple Sclerosis (Houndmills, Basingstoke, England) 2015 May;21(6):780-5.
16. All-Russian Society of Neurologists. Demyelinating Diseases Section. New drugs (tizabri, gilenia, movectro) for pathogenetic treatment of multiple sclerosis: recommendations. Moscow: Zdorovye cheloveka; 2011. 140 p. (In Russian).
17. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012 Apr;78(14):1069-78.
18. Alifirova VM, Bisaga GN, Boyko AN, Bryukhov VV, Davydovskay MV, Zakharova MN, Zakharova EV, Malkova NA, Popova EV, Salogub GN, Sivertseva SA, Troshina EA, Khachanova NV, Schmidt TE. Clinical recommendations on the use of alemtuzumab (lemtrada). SS Korsakov Journal of Neurology and Pshychiatry 2017;117(2-2):115-26 (In Russian).
19. Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK. Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs 2017 Jan;3(1):33-50.
20. Holmøy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab – a case for better preventive strategies. BMC Neurology 2017 Apr;17(1):65-8.
21. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, De Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2017 Jan;376(3):209-20.
22. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. The New England Journal Medicine 2017 Jan;376(3):221-34.
23. Stolyarov ID, Petrov AM, Votintseva MV, Ivaskova EV. Gilenia: new prospects in multiple sclerosis treatment. Medical Council 2011;9-10:108-11 (In Russian).
24. Kappos L, Boyko AN. Application of tablets in multiple sclerosis treatment: current state of the problem. SS Korsakov Journal of Neurology and Psychiatry 2014;114(2-2):63-71 (In Russian).
25. Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple Sclerosis (Houndmills, Basingstoke, England) 2014 Apr;20(4):471-80.
26. Carpenter AF, Goodwin SJ, Bornstein PF, Larson AJ, Markus CK. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: here come the opportunistic infections? Multiple Sclerosis (Houndmills, Basingstoke, England) 2017 Feb;23(2):297-99.
27. Alifirova VM, Boyko AN, Vlasov YaV, Davydovskaya MV, Zakharova MN, Malkova NA, Popova EV, Sivertseva SA, Spirin NN, Khachanova NV, Schmidt TE. Clinical recommendations for the use of dimethyl fumarate in remitting-relapsing multiple sclerosis treatment. SS Korsakov Journal of Neurology and Psychiatry 2017;117(1):97-102 (In Russian).
28. Stolyarov ID, Petrov AM, Gorokhova TV. Teriflunomide in remitting-relapsing multiple sclerosis therapy: efficacy and safety. Neurological Journal 2013;18(2):48-51 (In Russian).
29. Alifirova MV, Bakhtiyarova KZ, Belov AN, Bysaga GN, Boyko AN, Boyko OV, Vlasov YaV, Volkova LI, Goncharova ZA, Davydovskaya MV, Zakharova MN, Kotov SV, Lashch NYu, Malkova NA, Petrov AM, Popova EV, Severtseva SA, Sokolova IA, Spirin NN, Stolyarov ID, Streknev AG, Totolyan NA, Khachanova NV, Sherman MI, Schmidt TE, Khabirov FA., Yampolskaya-Gosteva IA. Clinical guidelines for the use of teriflunomide. SS Korsakov Journal of Neurology and Psychiatry 2016;116(10-2):98-104 (In Russian).
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]